{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:21:27Z","timestamp":1789928487436,"version":"4.0.1"},"publisher-location":"Chichester, UK","reference-count":25,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd009354.pub2","type":"reference-entry","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T13:20:25Z","timestamp":1380633625000},"source":"Crossref","is-referenced-by-count":20,"title":["Enzyme replacement therapy with laronidase (Aldurazyme<sup>\u00ae<\/sup>) for treating mucopolysaccharidosis type I"],"prefix":"10.1002","author":[{"given":"Elisabeth","family":"Jameson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E","family":"Wraith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,9,26]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD009354.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"issue":"5","key":"10.1002\/14651858.CD009354.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"Journal of Pediatrics"},{"issue":"55","key":"10.1002\/14651858.CD009354.pub2-BIB3|cit3","first-page":"1","article-title":"Enzyme replacement therapy and \/ or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure","volume":"6","author":"Rue","year":"2011","journal-title":"Orphanet Journal of Rare Disease"},{"issue":"1","key":"10.1002\/14651858.CD009354.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ymgme.2008.10.009","article-title":"A dose-optimisation trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I","volume":"96","author":"Giugliani","year":"2009","journal-title":"Molecular Genetics and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD009354.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.GIM.0000154299.22120.6A","article-title":"Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome","volume":"7","author":"Grewal","year":"2005","journal-title":"Genetics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009354.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD009354.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/archopht.125.10.1353","article-title":"Ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy","volume":"125","author":"Pitz","year":"2007","journal-title":"Archives of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD009354.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1542\/peds.2006-2156","article-title":"Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"120","author":"Wraith\u00a0JE","year":"2007","journal-title":"Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD009354.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jpeds.2008.07.004","article-title":"Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients","volume":"154","author":"Wynn","year":"2009","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD009354.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1164\/ajrccm.152.3.7663792","article-title":"Standardization of spirometry, 1994 update. American Thoracic Society","volume":"152","year":"1995","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD009354.pub2-BIB11|cit11","unstructured":"Visual Rx. Online NNT Calculator www.nntonline.net\/"},{"issue":"18","key":"10.1002\/14651858.CD009354.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease","volume":"160","author":"Charrow","year":"2000","journal-title":"Archives of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD009354.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD009354.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00431-011-1644-x","article-title":"Diagnosis and treatment in mucopolysaccharidosis I: findings from the MPS I Registry","volume":"171","author":"D'Aco","year":"2012","journal-title":"European Journal of Pediarics"},{"key":"10.1002\/14651858.CD009354.pub2-BIB15|cit15","unstructured":"Genzyme Therapeutics Aldurazyme \u00ae (Laronidase) www.aldurazyme.com\/pdf\/az_us_hc_pi.pdf"},{"key":"10.1002\/14651858.CD009354.pub2-BIB16|cit16","unstructured":"Higgins JPT Altman DG Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 2011"},{"issue":"7414","key":"10.1002\/14651858.CD009354.pub2-BIB17|cit17","first-page":"557","article-title":"Measuring inconsistencies in meta-analyses","volume":"327","author":"Higgins","journal-title":"2003"},{"key":"10.1002\/14651858.CD009354.pub2-BIB18|cit18","unstructured":"Deeks JJ Higgins JPT Altman DG on behalf of the Cochrane Statistical Methods Group Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org 2011"},{"issue":"3","key":"10.1002\/14651858.CD009354.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalance of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD009354.pub2-BIB20|cit20","unstructured":"Genzyme Corporation MPS I Registry www.lsdregistry.net\/mpsiregistry\/"},{"issue":"1","key":"10.1002\/14651858.CD009354.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1542\/peds.2008-0416","article-title":"Mucolpolysaccharidosis I: management and treatment guidelines","volume":"123","author":"Muenzer","year":"2009","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD009354.pub2-BIB22|cit22","first-page":"3421","article-title":"The mucopolysaccharidoses","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"Neufeld","year":"2001"},{"key":"10.1002\/14651858.CD009354.pub2-BIB23|cit23","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"4","key":"10.1002\/14651858.CD009354.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.GIM.0000078027.83236.49","article-title":"Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature","volume":"5","author":"Terlato","year":"2003","journal-title":"Genetics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009354.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"American Journal of Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD009354.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:31:46Z","timestamp":1628548306000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD009354.pub2"}},"subtitle":[],"editor":[{"given":"Elisabeth","family":"Jameson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,9,26]]},"references-count":25,"aliases":["10.1002\/14651858.cd009354.pub3"],"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009354.pub2","relation":{},"subject":[],"published":{"date-parts":[[2013,9,26]]}}}